Rob Stein Rob Stein is a Correspondent and Senior Editor on NPR's Science Desk.
Rob Stein, photographed for NPR, 22 January 2020, in Washington DC.
Stories By

Rob Stein

Mike Morgan/NPR
Rob Stein, photographed for NPR, 22 January 2020, in Washington DC.
Mike Morgan/NPR

Rob Stein

Correspondent and Senior Editor, Science Desk

Rob Stein is a correspondent and senior editor on NPR's science desk.

An award-winning science journalist with more than 30 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues, and other science, medical, and health policy news.

Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.

Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science, the American Association for Cancer Research, and the Association of Health Care Journalists. He was twice part of NPR teams that won Peabody Awards.

Stein frequently represents NPR, speaking at universities, international meetings and other venues, including the University of Cambridge in Britain, the World Conference of Science Journalists in South Korea, and the Aspen Institute in Washington, DC.

Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.

Story Archive

The FDA is not expanding eligibility for 2nd COVID boosters

  • Download
  • <iframe src="https://www.npr.org/player/embed/1115756778/1115758268" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The Biden administration plans to offer updated booster shots in the fall. Mario Tama/Getty Images hide caption

toggle caption
Mario Tama/Getty Images

Summer boosters for people under 50 shelved in favor of updated boosters in the fall

  • Download
  • <iframe src="https://www.npr.org/player/embed/1114408611/1114417139" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A box of Evusheld, an antibody therapy developed by pharmaceutical company AstraZeneca for the prevention of COVID-19 in immunocompromised patients, is seen in February at the AstraZeneca facility for biological medicines in Sweden Jonathan Nackstrand/AFP via Getty Images hide caption

toggle caption
Jonathan Nackstrand/AFP via Getty Images

The FDA is trying to make "bivalent" COVID vaccines, which target two different antigens, available as soon as September. Robyn Beck/AFP via Getty Images hide caption

toggle caption
Robyn Beck/AFP via Getty Images

Reformulated COVID vaccine boosters may be available earlier than expected

  • Download
  • <iframe src="https://www.npr.org/player/embed/1113615330/1113615331" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

New COVID strain is highly contagious but symptoms mild for the vaccinated

  • Download
  • <iframe src="https://www.npr.org/player/embed/1113166723/1113166724" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

People under 50 might have a chance at a second booster shot the summer depending what federal health officials decide. Those 50 and older have been eligible for the shots since March. Paul Hennessy/SOPA Images/LightRocket via Getty Images hide caption

toggle caption
Paul Hennessy/SOPA Images/LightRocket via Getty Images

U.S. debates a summer booster for people under 50

  • Download
  • <iframe src="https://www.npr.org/player/embed/1112229721/1112316224" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Dr. Anthony Fauci, White House chief medical adviser and director of the NIAID, says he will leave his current position before the end of President Biden's first term, but he has not decided on an exact date. Greg Nash/Pool/AFP via Getty Images hide caption

toggle caption
Greg Nash/Pool/AFP via Getty Images

Experts question the FDA's COVID booster strategy ahead of autumn

  • Download
  • <iframe src="https://www.npr.org/player/embed/1111473802/1111473803" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Answering listeners' questions about COVID vaccines for young children

  • Download
  • <iframe src="https://www.npr.org/player/embed/1109883083/1109883874" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

FDA advisers recommend new COVID vaccines designed specifically to fend off omicron

  • Download
  • <iframe src="https://www.npr.org/player/embed/1108387089/1108387090" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The FDA considers the nation's next round of vaccines to battle COVID-19

  • Download
  • <iframe src="https://www.npr.org/player/embed/1108117715/1108117716" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

CDC OKs vaccinations for children 6 months to 5 years old

  • Download
  • <iframe src="https://www.npr.org/player/embed/1106094625/1106094626" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The omicron variant, though much more contagious than the delta strain, is still prevalent in the U.S. but is less likely than delta to cause long COVID, according to a new study. Spencer Platt/Getty Images hide caption

toggle caption
Spencer Platt/Getty Images

Omicron poses about half the risk of long COVID as delta, new research finds

  • Download
  • <iframe src="https://www.npr.org/player/embed/1094655028/1105790922" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

The FDA is reviewing COVID vaccines for children 5 and younger

  • Download
  • <iframe src="https://www.npr.org/player/embed/1104881719/1104881720" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Moderna says its vaccine is safe for babies, and travelers won't need COVID tests

  • Download
  • <iframe src="https://www.npr.org/player/embed/1104291228/1104291229" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript